October 3, 2019
September 17, 2019
Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting
September 10, 2019
Immusoft To Present At The International Conference On Lymphocyte Engineering 2019
September 9, 2019
Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer
August 28, 2019
Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing
August 8, 2019
Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
August 7, 2019
Retrotope Announces Full Enrollment of Phase 2/3 trial in patients with Infantile Neuroaxonal Dystrophy (INAD)
July 19, 2019
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors
June 10, 2019
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
May 31, 2019